Сравнение

Linaclotid vs. Terlipressin

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

851199-59-2

14636-12-5

Молекулярная масса

1526.74 g/mol

1227.37 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Terlipressin

Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Linaclotid	Terlipressin
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Linaclotid and Terlipressin?: Linaclotid is classified as "Исследования (прочее)", while Terlipressin is classified as "Исследования (прочее)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Linaclotid or Terlipressin?: The highest available evidence level is "РКИ на людях" for Linaclotid and "РКИ на людях" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Linaclotid and Terlipressin in Germany and the United States?: Германия: Linaclotid — Рецептурный, Terlipressin — Рецептурный. США: Linaclotid — Рецептурный, Terlipressin — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Linaclotid

Terlipressin

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Linaclotid and Terlipressin?

Linaclotid is classified as "Исследования (прочее)", while Terlipressin is classified as "Исследования (прочее)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Linaclotid or Terlipressin?

The highest available evidence level is "РКИ на людях" for Linaclotid and "РКИ на людях" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Linaclotid and Terlipressin in Germany and the United States?

Германия: Linaclotid — Рецептурный, Terlipressin — Рецептурный. США: Linaclotid — Рецептурный, Terlipressin — Рецептурный. These are factual summaries with source and review date on the individual pages.